83
The Canadian health authorities have just approved a drug, Albrioza, despite not having completed all the research phases. The Canadian regulatory agency has authorized its use with the results seen in only 137 patients. Although its approval is conditional, that is, the permit could be reversed if the results are not as satisfactory at the end of the studies and benefits for patients are not finally demonstrated. Pressure from patients, who have hardly any treatment options, has led Canada to justify its decision “because of the few therapeutic options available to ALS patients.” “Now the benefits of Albrioza outweigh the risks,” argues the Canadian Ministry of Health, which has become… See More